Company Spotlight: How to cut hospital waiting lists and make money

The term "bed-blocking" entered the lexicon around the same time as "alcopops", "spin" and "diamond geezer".

The term "bed-blocking" entered the lexicon around the same time as "alcopops", "spin" and "diamond geezer". But the problem is not new. Patients have long tied up beds, either because they are slow to convalesce after surgery or have nowhere else (such as a nursing home) where they can go. The issue has been given new urgency by NHS target-setting. Free up beds more quickly and you improve patient throughput and reduce waiting lists.

Now a UK company has found a way of doing just that by tackling one of the prime causes of slow post-operative recovery: a fall-off in the rate at which oxygen is delivered around the body during surgery. Deltex Medical Group, which is traded on the AIM market, has invented a system for monitoring blood flow during and after surgery and allowing doctors to detect and deal with the problem through the administering of fluid and drugs.

Its monitoring system is called CardioQ. It draws data from a disposable probe that is inserted in the patient's oesophagus. A host of studies have shown CardioQ can cut recovery times by as much as two-fifths. Deltex has spent much of its time in the past 18 months persuading NHS trusts to assess the economics of CardioQ by trying it out in widescale tests. In most cases it has been funding the costs of data collection.

Now all that is changing. Medway NHS Trust in Kent adopted the system in April as a "standard of care" for all its moderate- and major-risk surgical and critical-care patients. The results of a post-procurement review showed that CardioQ cut an average of two days off the time patients stayed in hospital. In other words, the system pays for itself several times over. Deltex still has trials in another dozen or so UK hospitals, but these are expected to lead to firm orders soon.

The impact on sales - just £3m last year - will be dramatic. Deltex will make most of its money from the sale of disposable probes. It is reckoned that the deal with Medway NHS Trust will be worth upwards of £100,000 in probes - and there are 400 hospitals in the UK that could adopt the system. Deltex may not win them all, but it is worth noting that it recently appointed the former head of the NHS, Sir Duncan Nichol, as a non-executive director. That surely cannot harm its marketing effort.

At Deltex's recent shareholders' annual meeting, the chairman, Nigel Keen, said there was good feedback from the other NHS trusts auditing the results of their CardioQ trials. He suggested it was now a question of when, not if, the system was adopted on a widespread basis. There was also a good chance of a hospital in Europe or the US announcing a deal shortly. Deltex is well advanced with its marketing in parts of Europe (France especially) and the US, where CardioQ received upgraded regulatory approvals last year.

All of this has to be put in the context of a company valued on the stock market at just £16m. That figure may rise as Deltex issues more shares to fund working capital when sales build up. But this is a small company in what is potentially a big market. That market could be bigger still. Earlier this year, Deltex launched a softer probe which can be used on conscious patients - widening the range of applications for CardioQ.

Thanks to a soggy stock market, the shares have been treading water for most of this year, despite the mounting evidence that CardioQ has proved itself. I reckon they are worth picking up on a two-year view at the current 26.5p.

Now, one for risk-takers. Eurodis Electron is one of Europe's biggest distributors of electronic components - not a good market since 2001. In the past two years, Eurodis has racked up losses of £76m and only saved itself from oblivion by raising £57m in new money. Because of a shortage of cash at critical periods last year, it lost market share, which will take time to rebuild.

Despite that, all but one of its major suppliers has stuck with the company and the market has clearly turned for the better. The last set of figures had an air of throwing in the kitchen sink about them and the board has been busy picking up shares at 3p and 4p a time since they were announced.

The first priority for Eurodis will be to regain market share, so profits will lag, despite a lot of cost-cutting in the past year. But at the current 3p, the company is valued at about £28m, a touch less than net worth. Even last year sales were £225m, which gives some idea of the recovery potential. But it is probably not one for light sleepers.

Independent Partners; request a free guide on NISAs from Hargreaves Lansdown

Arts and Entertainment
Sheridan Smith as Cilla Black and Ed Stoppard as her manager Brian Epstein
tvCilla Episode 2 review: Grit under the glamour in part two of biopic series starring Sheridan Smith
David Moyes and Louis van Gaal
Former Governor of Alaska Sarah Palin, left, with her daughter, Bristol
newsShe's 'proud' of eldest daughter, who 'punched host in the face'
New Zealand fly-half Aaron Cruden pictured in The Zookeeper's Son on a late-night drinking session
A cabin crew member photographed the devastation after one flight
Life and Style
Carol O'Brien, whose son Rob suffered many years of depression
healthOne mother's story of how London charity Maytree helped her son with his depression
Life and Style
food + drink
Arts and Entertainment
The cover of Dark Side of the Moon
musicCan 'The Endless River' carry on the tradition? See for yourself
Rob Merrick's Lobby Journalists were playing Ed Balls' Labour Party MPs. The match is an annual event which takes place ahead of the opening of the party conference
newsRob Merrick insistes 'Ed will be hurting much more than me'
A new app has been launched that enables people to have a cuddle from a stranger
voicesMaybe the new app will make it more normal to reach out to strangers
Liam Payne has attacked the media for reporting his tweet of support to Willie Robertson and the subsequent backlash from fans
peopleBut One Direction star insists he is not homophobic
Life and Style
healthFor Pure-O OCD sufferers this is a reality they live in
Life and Style
Sexual health charities have campaigned for the kits to be regulated
healthAmerican woman who did tells parents there is 'nothing to be afraid of'
Life and Style
Arts and Entertainment
The John Peel Lecture has previously been given by Pete Townshend of The Who, Billy Bragg and Charlotte Church
musicGodfather of punk will speak on 'free music in a capitalist society'
peopleAt least it's for a worthwhile cause
Shoppers in Covent Garden, London, celebrate after they were the first to buy the iPhone 6, released yesterday
Finacial products from our partners
Property search
Latest stories from i100
Have you tried new the Independent Digital Edition apps?
Independent Dating

By clicking 'Search' you
are agreeing to our
Terms of Use.

ES Rentals

    iJobs Job Widget
    iJobs Money & Business

    Trainee / Experienced Recruitment Consultants

    £20000 - £25000 per annum + OTE £40,000: SThree: SThree are a global FTSE 250 ...

    Trainee Recruitment Consultant - Soho

    £20000 - £25000 per annum + OTE £40000: SThree: As a Recruitment Consultant, y...

    Trainee Recruitment Consultants - Banking & Finance

    £20000 - £25000 per annum + OTE £40,000: SThree: SThree Group have been well e...

    Quantitative Risk Manager

    Up to £80000: Saxton Leigh: My client, a large commodities broker, is looking ...

    Day In a Page

    A roller-coaster tale from the 'voice of a generation'

    Not That Kind of Girl:

    A roller-coaster tale from 'voice of a generation' Lena Dunham
    London is not bedlam or a cradle of vice. In fact it, as much as anywhere, deserves independence

    London is not bedlam or a cradle of vice

    In fact it, as much as anywhere, deserves independence
    Vivienne Westwood 'didn’t want' relationship with Malcolm McLaren

    Vivienne Westwood 'didn’t want' relationship with McLaren

    Designer 'felt pressured' into going out with Sex Pistols manager
    Jourdan Dunn: Model mother

    Model mother

    Jordan Dunn became one of the best-paid models in the world
    Apple still coolest brand – despite U2 PR disaster

    Apple still the coolest brand

    Despite PR disaster of free U2 album
    Scottish referendum: The Yes vote was the love that dared speak its name, but it was not to be

    Despite the result, this is the end of the status quo

    Boyd Tonkin on the fall-out from the Scottish referendum
    Manolo Blahnik: The high priest of heels talks flats, Englishness, and why he loves Mary Beard

    Manolo Blahnik: Flats, Englishness, and Mary Beard

    The shoe designer who has been dubbed 'the patron saint of the stiletto'
    The Beatles biographer reveals exclusive original manuscripts of some of the best pop songs ever written

    Scrambled eggs and LSD

    Behind The Beatles' lyrics - thanks to Hunter Davis's original manuscript copies
    'Normcore' fashion: Blending in is the new standing out in latest catwalk non-trend

    'Normcore': Blending in is the new standing out

    Just when fashion was in grave danger of running out of trends, it only went and invented the non-trend. Rebecca Gonsalves investigates
    Dance’s new leading ladies fight back: How female vocalists are now writing their own hits

    New leading ladies of dance fight back

    How female vocalists are now writing their own hits
    Mystery of the Ground Zero wedding photo

    A shot in the dark

    Mystery of the wedding photo from Ground Zero
    His life, the universe and everything

    His life, the universe and everything

    New biography sheds light on comic genius of Douglas Adams
    Save us from small screen superheroes

    Save us from small screen superheroes

    Shows like Agents of S.H.I.E.L.D are little more than marketing tools
    Reach for the skies

    Reach for the skies

    From pools to football pitches, rooftop living is looking up
    These are the 12 best hotel spas in the UK

    12 best hotel spas in the UK

    Some hotels go all out on facilities; others stand out for the sheer quality of treatments